Leerink Partners Initiates Coverage On Kailera Therapeutics with Outperform Rating, Announces Price Target of $36

Benzinga Newsdesk www.benzinga.com Positive 71.5%

Neg 0% Neu 0% Pos 71.5%

Leerink Partners analyst David Risinger initiates coverage on Kailera Therapeutics (NASDAQ:KLRA) with a Outperform rating and announces Price Target of $36.